U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07090369) titled 'Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer' on July 15.
Brief Summary: This phase 1b trial is designed to evaluate the safety and tolerability of olaparib in combination with 177Lutetium-Prostate Specific Membrane Antigen (177 Lu-PSMA) and pembrolizumab in patients with metastatic castration resistant prostate cancer (mCRPC).
Study Start Date: Nov. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Intervention:
DRUG: Olaparib (300 mg BID)
oral tablet
DRUG: Pembrolizu...